YONG LI to Biomarkers, Tumor
This is a "connection" page, showing publications YONG LI has written about Biomarkers, Tumor.
Connection Strength
0.638
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomark. 2025 Jun; 42(6):18758592251344936.
Score: 0.127
-
Carnitine palmitoyl transferase 1A is a novel diagnostic and predictive biomarker for breast cancer. BMC Cancer. 2021 Apr 15; 21(1):409.
Score: 0.095
-
Mutant p53 as an Antigen in Cancer Immunotherapy. Int J Mol Sci. 2020 Jun 08; 21(11).
Score: 0.090
-
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020 01 30; 19(1):19.
Score: 0.088
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
Score: 0.086
-
Prognostic stratification in DLBCL patients with aberrant MYC gene. Br J Haematol. 2024 Nov; 205(5):1782-1793.
Score: 0.030
-
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma. Oncoimmunology. 2024; 13(1):2384667.
Score: 0.030
-
AFAP1-AS1: a rising star among oncogenic long non-coding RNAs. Sci China Life Sci. 2021 Oct; 64(10):1602-1611.
Score: 0.024
-
Upregulation of long non-coding RNA LOC284454 may serve as a new serum diagnostic biomarker for head and neck cancers. BMC Cancer. 2020 Sep 24; 20(1):917.
Score: 0.023
-
CircARHGAP12 promotes nasopharyngeal carcinoma migration and invasion via ezrin-mediated cytoskeletal remodeling. Cancer Lett. 2021 01 01; 496:41-56.
Score: 0.023
-
Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019 08 23; 18(1):128.
Score: 0.021